ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - Generic Drug Details

What are the generic drug sources for estrogens, conjugated; medroxyprogesterone acetate and what is the scope of patent protection?

Estrogens, conjugated; medroxyprogesterone acetate is the generic ingredient in four branded drugs marketed by Wyeth Pharms Inc and Wyeth Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

US Patents:	0
Tradenames:	4
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
DailyMed Link:	ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE at DailyMed

Recent Clinical Trials for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Far Eastern Memorial Hospital	Phase 4
Selmo Geber	N/A
Erasmus Medical Center	Phase 4

See all ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE clinical trials

Pharmacology for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03DA	Pregnen (4) derivatives
G03D	PROGESTOGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03DA	Pregnen (4) derivatives
G03D	PROGESTOGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

L02AB	Progestogens
L02A	HORMONES AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-001	Nov 17, 1995		RX	Yes	Yes
Wyeth Pharms Inc	PREMPHASE (PREMARIN;CYCRIN 14/14)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-002	Dec 30, 1994		DISCN	No	No
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-005	Jun 4, 2003		RX	Yes	Yes

Expired US Patents for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-005	Jun 4, 2003	RE36247
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995	5,547,948
Wyeth Pharms Inc	PREMPRO (PREMARIN;CYCRIN)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-001	Dec 30, 1994	RE36247

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE Market Analysis and Financial Projection

Last updated: April 26, 2026

Market dynamics and financial trajectory for conjugated estrogens plus medroxyprogesterone acetate

Conjugated estrogens, and medroxyprogesterone acetate (generic name: conjugated estrogens/medroxyprogesterone acetate, CEE/MPA) remains a mature, commoditized hormone therapy franchise in the US and other established markets. The product’s financial trajectory is shaped by (1) post-2017 generic penetration and channel-based price competition, (2) FDA labeling constraints and prescriber caution linked to long-term safety discourse, and (3) the shift to lower-dose, alternative routes, and newer regimens that reduce addressable demand growth for oral CEE/MPA.

---

Where does this drug sit in the market structure?

CEE/MPA is best characterized as a late-cycle, multi-source “maintenance” therapy rather than a growth engine. Key dynamics:

• Originator-to-generic conversion is complete in most major markets. In the US, CEE/MPA is widely available in generic versions, which compress margins and drive volume-based revenue.
• Demand is persistent but not expanding. Hormone therapy is sustained by symptom management (moderate-to-severe vasomotor symptoms and prevention of postmenopausal osteoporosis for selected patients), but initiation is constrained by benefit-risk framing and patient stratification.
• Oral administration faces structural headwinds. Clinicians and payers increasingly favor transdermal or other hormone formulations for specific safety profiles, lowering incremental uptake.

Regulatory anchor influencing prescriber behavior: FDA labels position HRT products as having risks that require individualized use at the lowest effective dose for the shortest duration, with boxed warnings about endometrial cancer risk when progestogen is not used with estrogen, and boxed warnings on other serious risks typical to systemic hormone therapies (see FDA label framework and boxed warnings). (Source: FDA label overview for estrogen/progestin products [1])

---

What are the current commercial drivers and constraints?

Drivers

• Long-duration patient persistence in some cohorts: Users already on oral CEE/MPA often remain on therapy, which stabilizes revenue even when new starts soften.
• Formulary coverage keeps access intact: Because the therapy is inexpensive in generic form, plan coverage tends to remain broad unless a plan actively restricts oral agents in favor of alternatives.
• Indication pull remains specific but real: FDA indication language continues to support CEE/MPA for vasomotor symptoms and prevention of osteoporosis in appropriate populations. (Source: FDA label information [1])

Constraints

• Risk perception limits new starts: Ongoing safety risk discourse historically reduced initiation rates versus earlier eras.
• Substitution pressure: Clinicians can switch to different estrogen-progestin combinations, reduced-dose regimens, or alternative routes, particularly when tailoring to bleeding risk and thromboembolic risk concerns.
• Volume declines in mature categories: Even with stable prevalence, the category tends to track demographic aging less than proportionally to pricing erosion.

---

How does generic competition shape the financial trajectory?

Generic entry drives revenue mechanics:

• Price erosion dominates unit economics. For mature generics, revenue generally follows volume minus declining price per unit. Even stable adherence does not offset pricing compression.
• Manufacturer differentiation shifts to procurement and supply reliability. In generics, competitive advantage often migrates from differentiation to contract position with wholesalers, PBMs, and large pharmacy chains.

Practical implication for financials: The franchise typically shows:

• Revenue stability with declining revenue per script
• Gross margin compression
• Limited operating leverage

This pattern is consistent with multi-source systemic hormone therapies where originator exclusivity is long expired and most value accrues to supply chain efficiency and contract terms.

---

What does the regulatory and labeling landscape imply for sales velocity?

CEE/MPA systemic HRT labels include boxed warnings and require careful selection. The FDA boxed warning framework for estrogen and progestin products influences:

• Prescriber decisioning: “Lowest effective dose” and shortest duration instructions limit dose escalation strategies.
• Patient counseling: Longer-term use requires periodic reassessment, reducing persistent high-dose cohorts.
• Therapy discontinuation: Some patients stop after symptom improvement, and this increases churn in the absence of new starts.

(Anchor: FDA boxed warning and systemic hormone therapy labeling structure [1])

---

How do the US and ex-US markets typically differ?

US

• Highest generic penetration, largest price competition.
• More active payer management for oral HRT relative to certain alternatives.
• Stronger safety-driven prescribing caution after long-term safety narratives.

Ex-US

• Varied access and regulatory timing: some regions retain single-brand or limited generic competition for longer.
• Pricing still compresses over time, but the slope can be shallower depending on local manufacturing capacity and reimbursement policy.

Net effect: The financial trajectory tends to show earlier and steeper revenue decline in the US and a delayed decline in lower-penetration geographies.

---

What is the expected revenue and earnings profile (directional trajectory)?

Given the drug’s status as a mature oral generic, the likely trajectory is:

1. Top-line: Flat-to-declining, driven by limited net new initiation and continuing substitution to alternatives.
2. Margins: Lower than historically branded levels, with operating earnings driven by contract pricing and supply chain costs.
3. Capital intensity: Lower R&D intensity than breakthrough therapeutics, but manufacturing and regulatory compliance costs remain material.
4. Cash flow: Typically steady due to established manufacturing and predictable demand, but vulnerable to price resets and procurement pressure.

This profile matches systemic hormone therapies in mature phases, where demand is persistent but value extraction is constrained by generics and payer negotiations.

---

What competitive threats matter most?

Product-class substitution

• Transdermal estrogen formulations and different progestins can capture patients seeking risk-optimized regimens.
• Lower-dose and alternative schedules can reduce bleeding-related discontinuation and physician preference shifts.

Payer restrictions

• Step edits and formulary tiering can steer patients to preferred generics or preferred alternatives.
• PBMs may encourage therapeutic substitution within systemic HRT categories.

Channel concentration risk

• Large wholesaler and chain contracts can reset annual pricing, forcing margin trade-offs.

---

How should stakeholders underwrite this franchise in financial models?

For investment, R&D partnering, or commercial planning:

• Forecast structure: model a “base adherence” scenario (existing users) plus a “new starts” scenario that declines or remains flat in line with category-level initiation trends.
• Price assumptions: include annual price erosion consistent with generic procurement dynamics and contract repricing cycles.
• Mix shift: account for displacement from oral CEE/MPA to other HRT formulations (especially transdermal).

---

What policies and claims restrictions are most relevant?

The FDA labeling framework governs:

• boxed-warning communication and contraindications
• need for individualized risk-benefit assessment
• “lowest effective dose” and periodic reassessment

These restrictions dampen category-level acceleration. (Source: FDA labeling framework for systemic estrogen with progestin therapy [1])

---

Key Takeaways

• Conjugated estrogens/medroxyprogesterone acetate is a mature oral systemic hormone therapy with stable but non-growing demand and strong generic price pressure.
• Financial trajectory is driven more by contract and pricing resets than by new clinical value creation.
• Regulatory labeling and boxed warnings constrain initiation and long-term continuation patterns, sustaining churn and substitution to alternative regimens.
• Underwriting should use a two-component demand model (existing persistence plus soft new starts) and incorporate recurring generic price erosion.

---

FAQs

1) Is CEE/MPA still a meaningful revenue product class?

Yes. It remains clinically used and widely available, but its economics reflect generic competition rather than premium pricing.

2) What most impacts revenue for generic CEE/MPA manufacturers?

Wholesale and PBM contract pricing, supply continuity, and mix shifts as prescribers move among systemic HRT options.

3) Does FDA labeling directly constrain sales growth?

It constrains new initiation and affects dosing and duration behavior through boxed warnings and risk-benefit requirements. (Source: FDA label framework [1])

4) Where is the biggest downside risk for financials?

Fast price resets during procurement cycles and category substitution toward transdermal or alternative progestin regimens.

5) Is there an upside case?

Upside typically comes from better procurement positioning and stable persistence in existing user cohorts, not from growth in clinical penetration at category level.

---

References

[1] U.S. Food and Drug Administration (FDA). (n.d.). Labeling for estrogen and progestin hormone therapy products and boxed warning framework. FDA drug labeling resources. https://www.accessdata.fda.gov/